NCT04464967 2021-05-12Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersNKGen Biotech, Inc.Phase 1/2 Withdrawn
NCT00005842 2013-02-11Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic CancerNational Cancer Institute (NCI)Phase 1 Completed24 enrolled